Developer docs
API playgroundTry for free, no card

Search company profiles

Timberlyne Therapeutics

Full company profile

uuid0000i9x

Namestring
Timberlyne Therapeutics
Legal namestring
Timberlyne Therapeutics
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company founded in 2024 and headquartered in San Diego, California. The company focuses on developing and commercializing transformational therapies for autoimmune diseases, with a stated mission of bringing life-changing medicines to patients with significant unmet medical need. Timberlyne operates with a lean team of 11-50 employees and pursues a capital-efficient asset-acquisition model, leveraging its team's drug development expertise to in-license best-in-class assets targeting compelling biological mechanisms and applying them to disease areas with significant unmet need.

The company's lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity (CDC) that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. By targeting CD38, CM313 is designed to modulate multiple arms of the immune system, with the company claiming potential for both rapid and durable responses across a range of autoimmune diseases. CM313 has been clinically tested in Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE), and relapsed/refractory Multiple Myeloma, and Timberlyne plans to develop it across a broad range of additional autoimmune indications.

Timberlyne is pre-revenue and has not yet commercialized any product. Its revenue model is expected to depend on successful clinical development and regulatory approval of CM313 and future pipeline programs, with commercialization planned upon approval. The company has not disclosed pricing, distribution channels, or marketing infrastructure, consistent with its pre-commercial stage. As of January 2025, Timberlyne raised $180 million in a financing round co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from 3H Health Investment, Boyu Capital, Braidwell, and Lilly Asia Ventures. Daniel Curran serves as Chief Executive Officer and Christian Fougner as VP of Business Operations and Co-Founder.

Short descriptiontext

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an anti-CD38 IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity, for autoimmune diseases including ITP, SLE, and multiple myeloma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical therapeutics, monoclonal antibody development, autoimmune disease treatments, clinical-stage immunology, CD38 targeted therapy
Industry2 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceuticals / Autoimmune Disease Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company developing transformational therapies for autoimmune diseases. Revenue model will depend on successful clinical development and regulatory approval of CM313 and future pipeline programs.

timberlyne-tx.com
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38 on plasma cells, NK cells, and other immune cells. The asset is being advanced across multiple autoimmune indications, including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, with the goal of bringing life-changing medicines to patients with high unmet need.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company with a single lead product, CM313. CM313 is an IgG1 monoclonal antibody targeting CD38, developed for the treatment of autoimmune diseases. The company plans to develop CM313 across a broad range of autoimmune indications including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma.

Product and service1 record
1CM313
CategoryBiopharmaceutical / Monoclonal Antibody
Description

CM313 is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. It is being developed to modulate multiple arms of the immune system and produce both rapid and durable responses across autoimmune indications. CM313 has been tested in Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, and Timberlyne plans to develop it across a broad range of autoimmune indications.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage biotech developing antibody therapeutics for autoimmune diseases, including FcRn antagonist efgartigimod (Vyvgart). Operates in the same autoimmune biologics space as Timberlyne with a similar asset-acquisition and development approach and overlapping indication strategy.

TypeDirect peer
Description

Biotech originally involved in co-development of isatuximab (CD38 antibody) and known for antibody therapeutic development in hematology and autoimmune diseases. Relevant peer given its CD38 antibody heritage and focus on antibody-based autoimmune therapies.

TypeDirect peer
Description

Commercializes isatuximab (Sarclisa), a CD38-targeting monoclonal antibody approved for multiple myeloma. Competes head-to-head with Timberlyne in the CD38 antibody class with significantly greater resources and global commercial reach.

TypeDirect peer
Description

Clinical-stage biotech developing antibody therapies for autoimmune diseases, including FcRn-targeting candidates. Comparable as a focused autoimmune antibody developer with similar capital structure and clinical-stage profile to Timberlyne.

TypeBroad incumbent
Description

Global biopharmaceutical company specializing in immunology and neurology, with approved autoimmune biologics (e.g., Cimzia, Rystiggo). Comparable as a focused autoimmune biologics developer and likely competitor for autoimmune market share.

TypeEmerging player
Description

Clinical-stage biotech developing targeted protein degraders for immunology and autoimmune diseases. Comparable as a clinical-stage immunology-focused developer pursuing differentiated mechanisms in the autoimmune space.

TypeBroad incumbent
Description

Global biopharmaceutical company with a significant rare disease and autoimmune portfolio, including plasma-cell directed therapies. Comparable as a potential competitor or strategic acquirer in autoimmune indications.

TypeEmerging player
Description

Clinical-stage biotech developing cell therapies for autoimmune diseases, with overlapping indications such as SLE. Comparable as a clinical-stage autoimmune-focused biotech competing for similar patient populations and investor capital.

TypeDirect peer
Description

Developer of daratumumab (Darzalex), the leading CD38-targeting monoclonal antibody approved for multiple myeloma and being expanded into autoimmune indications. Directly competes with Timberlyne's CM313 in the same molecular target and overlapping disease areas.

10Bristol Myers Squibb
TypeBroad incumbent
Description

Large biopharmaceutical company with a deep autoimmune disease franchise (e.g., Zeposia, Sotyktu) and significant resources for in-licensing or developing competing CD38 antibodies in autoimmune indications.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Timberlyne Therapeutics

Biopharmaceuticals / Autoimmune Disease Therapeuticstimberlyne-tx.com

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an anti-CD38 IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity, for autoimmune diseases including ITP, SLE, and multiple myeloma.

What Timberlyne Therapeutics does

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company founded in 2024 and headquartered in San Diego, California. The company focuses on developing and commercializing transformational therapies for autoimmune diseases, with a stated mission of bringing life-changing medicines to patients with significant unmet medical need. Timberlyne operates with a lean team of 11-50 employees and pursues a capital-efficient asset-acquisition model, leveraging its team's drug development expertise to in-license best-in-class assets targeting compelling biological mechanisms and applying them to disease areas with significant unmet need.

The company's lead program is CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity (CDC) that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. By targeting CD38, CM313 is designed to modulate multiple arms of the immune system, with the company claiming potential for both rapid and durable responses across a range of autoimmune diseases. CM313 has been clinically tested in Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE), and relapsed/refractory Multiple Myeloma, and Timberlyne plans to develop it across a broad range of additional autoimmune indications.

Timberlyne is pre-revenue and has not yet commercialized any product. Its revenue model is expected to depend on successful clinical development and regulatory approval of CM313 and future pipeline programs, with commercialization planned upon approval. The company has not disclosed pricing, distribution channels, or marketing infrastructure, consistent with its pre-commercial stage. As of January 2025, Timberlyne raised $180 million in a financing round co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners, with participation from 3H Health Investment, Boyu Capital, Braidwell, and Lilly Asia Ventures. Daniel Curran serves as Chief Executive Officer and Christian Fougner as VP of Business Operations and Co-Founder.

Timberlyne Therapeutics firmographics

Firmographics
Name
Timberlyne Therapeutics
Legal name
Timberlyne Therapeutics
Website
https://timberlyne-tx.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an anti-CD38 IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity, for autoimmune diseases including ITP, SLE, and multiple myeloma.
Ownership category
akta.pro rank

Timberlyne Therapeutics industry classification

Industry
Product category
Biopharmaceuticals / Autoimmune Disease Therapeutics
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Biopharmaceutical therapeutics
  • Monoclonal antibody development
  • Autoimmune disease treatments
  • Clinical-stage immunology
  • CD38 targeted therapy

Where Timberlyne Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Timberlyne Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing transformational therapies for autoimmune diseases. Revenue model will depend on successful clinical development and regulatory approval of CM313 and future pipeline programs.

Go-to-market motion1 record

Timberlyne Therapeutics product offering

Product offering

Core offering

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38 on plasma cells, NK cells, and other immune cells. The asset is being advanced across multiple autoimmune indications, including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, with the goal of bringing life-changing medicines to patients with high unmet need.

Product overview

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company with a single lead product, CM313. CM313 is an IgG1 monoclonal antibody targeting CD38, developed for the treatment of autoimmune diseases. The company plans to develop CM313 across a broad range of autoimmune indications including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma.

Differentiator

Problem solved

Functional benefit

Products and services

  • CM313 CM313 is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38, a protein highly expressed on plasma cells, NK cells, and other immune cells. It is being developed to modulate multiple arms of the immune system and produce both rapid and durable responses across autoimmune indications. CM313 has been tested in Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, and Timberlyne plans to develop it across a broad range of autoimmune indications.

Companies that use Timberlyne Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Timberlyne Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Timberlyne Therapeutics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights5 records

Timberlyne Therapeutics competitors and assessment

Company assessment

Direct peers

  • Argenx: Commercial-stage biotech developing antibody therapeutics for autoimmune diseases, including FcRn antagonist efgartigimod (Vyvgart). Operates in the same autoimmune biologics space as Timberlyne with a similar asset-acquisition and development approach and overlapping indication strategy.
  • MorphoSys: Biotech originally involved in co-development of isatuximab (CD38 antibody) and known for antibody therapeutic development in hematology and autoimmune diseases. Relevant peer given its CD38 antibody heritage and focus on antibody-based autoimmune therapies.
  • Sanofi: Commercializes isatuximab (Sarclisa), a CD38-targeting monoclonal antibody approved for multiple myeloma. Competes head-to-head with Timberlyne in the CD38 antibody class with significantly greater resources and global commercial reach.
  • Immunovant: Clinical-stage biotech developing antibody therapies for autoimmune diseases, including FcRn-targeting candidates. Comparable as a focused autoimmune antibody developer with similar capital structure and clinical-stage profile to Timberlyne.
  • Janssen (Johnson & Johnson): Developer of daratumumab (Darzalex), the leading CD38-targeting monoclonal antibody approved for multiple myeloma and being expanded into autoimmune indications. Directly competes with Timberlyne's CM313 in the same molecular target and overlapping disease areas.

Broad incumbents

  • UCB: Global biopharmaceutical company specializing in immunology and neurology, with approved autoimmune biologics (e.g., Cimzia, Rystiggo). Comparable as a focused autoimmune biologics developer and likely competitor for autoimmune market share.
  • Takeda Pharmaceutical: Global biopharmaceutical company with a significant rare disease and autoimmune portfolio, including plasma-cell directed therapies. Comparable as a potential competitor or strategic acquirer in autoimmune indications.
  • Bristol Myers Squibb: Large biopharmaceutical company with a deep autoimmune disease franchise (e.g., Zeposia, Sotyktu) and significant resources for in-licensing or developing competing CD38 antibodies in autoimmune indications.

Emerging players

  • Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and autoimmune diseases. Comparable as a clinical-stage immunology-focused developer pursuing differentiated mechanisms in the autoimmune space.
  • Cabaletta Bio: Clinical-stage biotech developing cell therapies for autoimmune diseases, with overlapping indications such as SLE. Comparable as a clinical-stage autoimmune-focused biotech competing for similar patient populations and investor capital.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Timberlyne Therapeutics social profiles

Digital presence

Timberlyne Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Timberlyne Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Timberlyne Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Timberlyne Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Timberlyne Therapeutics

What does Timberlyne Therapeutics do?

Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing CM313, an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38 on plasma cells, NK cells, and other immune cells. The asset is being advanced across multiple autoimmune indications, including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma, with the goal of bringing life-changing medicines to patients with high unmet need.

When was Timberlyne Therapeutics founded?

Timberlyne Therapeutics was founded in 2024. It employs 1 to 10 people.

Where is Timberlyne Therapeutics based?

Timberlyne Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Timberlyne Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Timberlyne Therapeutics's main competitors?

Direct peers on record are Argenx, MorphoSys, Sanofi, Immunovant and Janssen (Johnson & Johnson). Broad incumbents are UCB, Takeda Pharmaceutical and Bristol Myers Squibb. Emerging players are Kymera Therapeutics and Cabaletta Bio.

Does Timberlyne Therapeutics have an API?

No public API is recorded for Timberlyne Therapeutics.

What industry is Timberlyne Therapeutics in?

Timberlyne Therapeutics's product category is Biopharmaceuticals / Autoimmune Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 62151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Phirda谁是中国血液肿瘤老大In 2025, BTK inhibitor Zelnitib and BCMA CAR-T Carvykti from Chinese firms Baidi and Legend sold nearly $6 billion, with Q1 sales reaching $1.7 billion. The article details a competitive landscape with Baidi and Legend leading, followed by Novartis, Yasheng, and DiZhi, and Biotech firms using bispecifics to compete.PR NewswireKeymed Biosciences Announces Annual Results of 2024Keymed Biosciences announced its 2024 annual results, reporting total revenue of RMB 430 million (21% year-on-year increase) and R&D expenditures of approximately RMB 730 million (23% YoY increase), with cash reserves of RMB 2.1 billion. The company secured three new drug approvals from China's NMPA for its flagship drug Stapokibart (CM310) across atopic dermatitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis, generating approximately RMB 40 million in sales within three and a half weeks of launch. Keymed expanded its global partnerships through licensing agreements with Belenos Biosciences, Platina Medicines Ltd, and Timberlyne Therapeutics, receiving combined upfront payments exceeding $61 million plus equity stakes, while also entering a joint development agreement with Prolium for CM355.Pulse 2.0Timberlyne Therapeutics: $180 Million (Series A) Raised For Advancing CM313Timberlyne Therapeutics closed a $180 million Series A to advance CM313, a CD38-targeting monoclonal antibody. The drug showed a 95% response rate in treatment-refractory immune thrombocytopenia in a published study. Keymed Biosciences holds exclusive rights outside China, with an undisclosed upfront payment and future milestones.Pulse 2.0Timberlyne: $180 Million (Series A) Raised To Develop Novel Therapies For Autoimmune DisordersTimberlyne Therapeutics closed an $180 million Series A to advance CM313, a CD38-targeting monoclonal antibody for autoimmune disorders. The drug showed a 95% response rate in treatment-refractory immune thrombocytopenia in a study published in the New England Journal of Medicine. Keymed Biosciences received an upfront payment and future milestones under the licensing agreement.Timberlyne-TxTimberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical NeedsTimberlyne Therapeutics closed a $180 million Series A financing to advance CM313, a CD38-targeting monoclonal antibody, for autoimmune diseases and cancers. The financing was led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners. CM313 showed a 95% response rate in a clinical study for treatment-refractory immune thrombocytopenia.InvestorshangoutTimberlyne Therapeutics Secures $180 Million for CM313 InnovationTimberlyne Therapeutics raised $180 million in Series A financing co-led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners. The funds will advance CM313, an anti-CD38 monoclonal antibody, which showed a 95% response rate in clinical studies for immune thrombocytopenia. The company will use the capital to further develop the drug toward commercialization.PR NewswireTimberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical NeedsTimberlyne Therapeutics closed a $180 million Series A financing to advance CM313, a CD38-targeting monoclonal antibody, for autoimmune diseases and cancers. The financing was led by Abingworth, Bain Capital Life Sciences, and Venrock Healthcare Capital Partners. CM313 showed a 95% response rate in a clinical study for treatment-refractory immune thrombocytopenia.